结核疫苗在中国、南非和印度的潜在影响建模
研究用结核分枝杆菌传播模型模拟中国、南非和印度2025年起接种假设结核疫苗至2050年的影响。结果显示,对已感染人群预防发病的疫苗影响力最大,三国发病率降幅分别为51%、52%和54%。
要点
- 对已感染人群预防发病的疫苗至2050年影响力最大。
- 仅对未感染人群有效的疫苗在高传播地区影响更大。
- 疫苗影响力取决于流行病学背景,需差异化研发策略。
核心结论
- 结核疫苗可产生显著人群层面影响,至2050年优先关注对已感染人群预防发病的疫苗。
研究设计与样本
- 校准结核分枝杆菌传播模型,使用中国、南非和印度年龄分层人口与流行病学数据。
- 模拟2025年起常规青少年接种和每10年大规模接种活动。
- 改变疫苗预防感染或发病、对未感染或已感染人群有效及保护持续时间等特征。
主要发现
- 对已感染人群预防发病、10年70%效力的疫苗至2050年发病率降幅在中国、南非和印度分别为51%、52%和54%。
- 预防再感染的疫苗影响力较低,三国发病率降幅分别为1%、12%和17%。
- 仅对未感染人群有效的疫苗,预防感染时发病率降幅为21%、37%和50%,预防发病时为19%、36%和51%。
临床怎么用
- 疫苗研发决策可优先考虑对已感染人群预防发病的疫苗以最大化至2050年人群影响。
- 在高传播地区,针对未感染人群预防感染或发病的疫苗也可能有用。
- 需根据各国流行病学背景制定差异化疫苗研发策略。
局限性
- 结果为假设疫苗的模型预测,非实际临床试验数据。
- 仅模拟中国、南非和印度三个高负担国家。
- 疫苗特征参数为设定情景,可能影响预测外推。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
More effective tuberculosis vaccines are needed to help reach World Health Organization tuberculosis elimination goals. Insufficient evidence exists on the potential impact of future tuberculosis vaccines with varying characteristics and in different epidemiological settings. To inform vaccine development decision making, we modeled the impact of hypothetical tuberculosis vaccines in three high-burden countries. We calibrated Mycobacterium tuberculosis (M.tb) transmission models to age-stratified demographic and epidemiological data from China, South Africa, and India. We varied vaccine efficacy to prevent infection or disease, effective in persons M.tb uninfected or infected, and duration of protection. We modeled routine early-adolescent vaccination and 10-yearly mass campaigns from 2025. We estimated median percentage population-level tuberculosis incidence rate reduction (IRR) in 2050 compared to a no new vaccine scenario. In all settings, results suggested vaccines preventing disease in M.tb-infected populations would have greatest impact by 2050 (10-year, 70% efficacy against disease, IRR 51%, 52%, and 54% in China, South Africa, and India, respectively). Vaccines preventing reinfection delivered lower potential impact (IRR 1, 12, and 17%). Intermediate impact was predicted for vaccines effective only in uninfected populations, if preventing infection (IRR 21, 37, and 50%) or disease (IRR 19, 36, and 51%), with greater impact in higher-transmission settings. Tuberculosis vaccines have the potential to deliver substantial population-level impact. For prioritizing impact by 2050, vaccine development should focus on preventing disease in M.tb-infected populations. Preventing infection or disease in uninfected populations may be useful in higher transmission settings. As vaccine impact depended on epidemiology, different development strategies may be required.
引用
- Harris RC, Sumner T, Knight GM, et al. Potential impact of tuberculosis vaccines in China, South Africa, and India. Sci Transl Med. 2020. PMID: 33028708. doi:10.1126/scitranslmed.aax4607
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。